Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Assets (2016 - 2025)

Organogenesis Holdings has reported Assets over the past 10 years, most recently at $598.7 million for Q4 2025.

  • Quarterly results put Assets at $598.7 million for Q4 2025, up 20.25% from a year ago — trailing twelve months through Dec 2025 was $598.7 million (up 20.25% YoY), and the annual figure for FY2025 was $598.7 million, up 20.25%.
  • Assets for Q4 2025 was $598.7 million at Organogenesis Holdings, up from $509.8 million in the prior quarter.
  • Over the last five years, Assets for ORGO hit a ceiling of $598.7 million in Q4 2025 and a floor of $319.2 million in Q1 2021.
  • Median Assets over the past 5 years was $453.3 million (2022), compared with a mean of $449.5 million.
  • Biggest five-year swings in Assets: soared 64.24% in 2021 and later dropped 3.53% in 2024.
  • Organogenesis Holdings' Assets stood at $443.3 million in 2021, then rose by 1.38% to $449.4 million in 2022, then rose by 2.37% to $460.0 million in 2023, then increased by 8.23% to $497.9 million in 2024, then rose by 20.25% to $598.7 million in 2025.
  • The last three reported values for Assets were $598.7 million (Q4 2025), $509.8 million (Q3 2025), and $461.1 million (Q2 2025) per Business Quant data.